Real‐world prevalence of PD ‐ L1 positivity in early‐stage/metastatic triple‐negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study
Authors:
- Corrado D'ARrigoCDCorrado D'ARrigo
- Sitki TuzlaliSTSitki Tuzlali
- Romualdo Barroso‐SousaRBRomualdo Barroso‐Sousa
- Nagi S El SaghirNSNagi S El Saghir
- Rebecca DentRDRebecca Dent
- Nataša Medić‐MilijićNMNataša Medić‐Milijić
- Gyungyub GongGGGyungyub Gong
- Shahin SayedSSShahin Sayed
- Tu Thai AnhTATu Thai Anh
- Alisan ZirtilogluAZAlisan Zirtiloglu
- Götz HartlebenGHGötz Hartleben
- Paula ToroPTPaula Toro
Open Access
- 22 February 2026
- journal article
- Published by Wiley in Histopathology
- Vol. 88 (7) , 1373-1384
Abstract
Aim: To understand whether the worldwide implementation of PD‐L1 testing in triple‐negative breast cancer (TNBC) can be achieved in routine clinical practice. Methods and results: The multicentre retrospective observational VANESSA study consecutively and uniformly enrolled patients treated with systemic therapy for early or metastatic (e/m)TNBC diagnosed between 2014 and 2017. PD‐L1 status was retrospectively assessed locally and centrally using the VENTANA PD‐L1 (SP142) Assay (PD‐L1 expression on tumour‐infiltrating immune cells covering ≥1% of the tumour area). The primary objective was to determine the prevalence of PD‐L1 positivity assessed locally on primary and/or metastatic tumour tissue. Concordance between local and central testing was a secondary endpoint. PD‐L1‐positive prevalence was 38% in eTNBC (728/1902) and 20% in mTNBC (30/152) and was higher in submitted tissue size >5 versus <5 mm diameter (eTNBC: 43% versus 16%; mTNBC: 24% versus 13%). Among 1967 samples tested both centrally and locally, concordance was 75% (Cohen's κ coefficient 0.52, 95% CI 0.48–0.55) and was similar regardless of cohort (eTNBC versus mTNBC), sample collection method (biopsy versus resection) or sample origin (primary versus metastatic). PD‐L1‐positive prevalence was higher by central versus local assessment (eTNBC: 55% versus 39%; mTNBC: 26% versus 20%). Conclusion: In this real‐world study, PD‐L1‐positive prevalence was lower than in prospective trials assessing PD‐L1 status centrally, lower in mTNBC than eTNBC, lower in smaller than larger tissue samples and lower by local than central assessment. These findings underline the importance of central PD‐L1 testing on sufficiently large samples to ensure optimal selection for therapies targeting PD‐(L)1 in mTNBC.Keywords
This publication has 44 references indexed in Scilit:
- Adjuvant Atezolizumab for Early Triple-Negative Breast CancerJAMA, 2025
- The prognostic value of the tumor-stroma ratio compared to tumor-infiltrating lymphocytes in triple-negative breast cancer: a reviewVirchows Archiv, 2025
- IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancerAnnals of Oncology, 2024
- Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancerVirchows Archiv, 2023
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAnnals of Oncology, 2021
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerAnnals of Oncology, 2021
- Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancerBreast Cancer Research and Treatment, 2021
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)Annals of Oncology, 2020
- LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trialAnnals of Oncology, 2020